IDYA — IDEAYA Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1676725 ·
Last close
$36.69
Market Cap
$3.54B
52W High
$42.68
52W Low
$25.54
ADV30
823,463
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 8,857,000 | — | -122,291,000 | -112,452,000 | 1,309,699,000 | 272,589,000 | 110,794,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 10,876,000 | — | -94,570,000 | -83,273,000 | 1,109,324,000 | 112,825,000 | 86,390,000 |
| Sep 2025 | 207,834,000 | — | 108,452,000 | 119,244,000 | 1,185,136,000 | 298,927,000 | 93,102,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-111,663,000
Investing CF
$-92,739,000
Financing CF
$362,822,000
CapEx
$-2,208,000
Dividends Paid
—
Buybacks
$-9,000
EPS Diluted TTM
$-1.94
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-947,530,000
Inventory
—
Receivables
$15,417,000
ST Investments
$556,366,000
EBIT TTM
$-216,953,000
Pretax Income TTM
$-175,020,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$234,127,008
EBITDA
$-214,195,008
Free Cash Flow
$-70,847,624
Enterprise Value
$2,827,391,744
Total Cash
$828,955,008
Total Debt
$29,307,000
Shares Out
96,489,484
Trailing EPS
$-1.92
Book Value
$12.44
ROE
-16.2%
ROA
-11.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 218,710,000 | -159,313,000 | -113,698,000 | 1,109,324,000 | 86,390,000 | 1,022,934,000 | -71,098,000 |
| Dec 2024 | 7,000,000 | -326,975,000 | -274,477,000 | 1,124,091,000 | 64,944,000 | 1,059,147,000 | -247,584,000 |
| Dec 2023 | 23,385,000 | -134,429,000 | -112,961,000 | 649,316,000 | 28,226,000 | 621,090,000 | -115,224,000 |
| Dec 2022 | 50,931,000 | -62,502,000 | -58,655,000 | 387,969,000 | 38,514,000 | 349,455,000 | -87,175,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.10
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $36.69 · call volume: 182 · put volume: 11
Expected Move to 2027-01-15:
±$8.35
(22.76%) —
implied range
$28.34 –
$45.04
· ATM straddle on $37.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACAD | ACADIA PHARMACEUTICALS INC | $3.56B | $20.68 | — |
| XENE | Xenon Pharmaceuticals Inc. | $3.58B | $36.94 | — |
| OGN | Organon & Co. | $3.61B | $13.73 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.63B | $75.08 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.38B | $26.92 | — |
News headlines (Yahoo Finance, 1h cache)
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
2026-09-28 10:00 · Yahoo
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-25 10:00 · Yahoo
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
2026-09-25 09:42 · Yahoo
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell L
2026-08-31 10:00 · Yahoo
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
2026-08-19 10:00 · Yahoo
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancer
2026-07-27 10:00 · Yahoo
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
2026-07-17 13:00 · Yahoo
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
2026-06-17 10:00 · Yahoo
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
2026-06-15 10:00 · Yahoo
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
2026-09-28 01:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.